Vertex Pharmaceuticals Inc (VRTX)
417.18
-1.64
(-0.39%)
USD |
NASDAQ |
May 09, 12:21
Vertex Pharmaceuticals Enterprise Value: 97.91B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 97.91B |
| May 07, 2024 | 95.69B |
| May 06, 2024 | 93.70B |
| May 03, 2024 | 93.33B |
| May 02, 2024 | 93.09B |
| May 01, 2024 | 93.60B |
| April 30, 2024 | 91.19B |
| April 29, 2024 | 92.17B |
| April 26, 2024 | 92.50B |
| April 25, 2024 | 92.55B |
| April 24, 2024 | 93.34B |
| April 23, 2024 | 94.42B |
| April 22, 2024 | 93.13B |
| April 19, 2024 | 91.67B |
| April 18, 2024 | 91.46B |
| April 17, 2024 | 91.36B |
| April 16, 2024 | 91.64B |
| April 15, 2024 | 92.47B |
| April 12, 2024 | 92.26B |
| April 11, 2024 | 93.21B |
| April 10, 2024 | 92.52B |
| April 09, 2024 | 94.30B |
| April 08, 2024 | 94.24B |
| April 05, 2024 | 94.87B |
| April 04, 2024 | 94.18B |
| Date | Value |
|---|---|
| April 03, 2024 | 95.42B |
| April 02, 2024 | 95.58B |
| April 01, 2024 | 98.44B |
| March 31, 2024 | 97.80B |
| March 28, 2024 | 96.82B |
| March 27, 2024 | 96.64B |
| March 26, 2024 | 96.94B |
| March 25, 2024 | 96.31B |
| March 22, 2024 | 96.21B |
| March 21, 2024 | 96.23B |
| March 20, 2024 | 95.30B |
| March 19, 2024 | 96.09B |
| March 18, 2024 | 95.11B |
| March 15, 2024 | 94.09B |
| March 14, 2024 | 94.37B |
| March 13, 2024 | 95.51B |
| March 12, 2024 | 95.32B |
| March 11, 2024 | 95.84B |
| March 08, 2024 | 95.62B |
| March 07, 2024 | 94.83B |
| March 06, 2024 | 95.17B |
| March 05, 2024 | 96.09B |
| March 04, 2024 | 98.31B |
| March 01, 2024 | 100.57B |
| February 29, 2024 | 97.46B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.39B
Minimum
Oct 05 2021
103.73B
Maximum
Jan 30 2024
61.36B
Average
60.67B
Median
Enterprise Value Benchmarks
| Amgen Inc | 219.16B |
| Eli Lilly and Co | 760.27B |
| Regeneron Pharmaceuticals Inc | 96.77B |
| Alpine Immune Sciences Inc | 3.914B |
| Editas Medicine Inc | 88.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.100B |
| Revenue (Quarterly) | 2.691B |
| Total Expenses (Quarterly) | 1.474B |
| EPS Diluted (Quarterly) | 4.21 |
| Gross Profit Margin (Quarterly) | 87.27% |
| Profit Margin (Quarterly) | 40.87% |
| Earnings Yield | 3.69% |
| Operating Earnings Yield | 4.04% |
| Normalized Earnings Yield | 3.852 |